Immunovaccine Expands Collaboration with Defence Research & Development Canada

"Preliminary animal studies revealed that Immunovaccine's DepoVax(TM) technology can reduce the number of immunizations required to induce antibodies against anthrax," remarked Dr. Marc Mansour, vice president of R&D at Immunovaccine Inc.

"We are encouraged by these results, and would like to continue our collaboration for developing an enhanced anthrax vaccine using the DepoVax(TM) technology. We are also expanding the program to look at other priority bioterrorism agents like Glanders," said Dr. Les Nagata, Head Biotechnology Section at DRDC.

Glanders is a deadly bacterial infection caused by Burkholderia mallei. As a biological weapons agent, Glanders could be used against humans and livestock. In their April 2007 report, the Department of Health and Human Services (HHS) identified Glanders as one of the top priorities for development of medical countermeasures.

DRDC is an agency of the Department of National Defence, responding to the scientific and technological needs of the Canadian Forces and national security communities. With a broad scientific program, DRDC actively collaborates with industry, international allies, academia, other government departments and the national security community. www.drdc-rddc.gc.ca.

Immunovaccine Inc. (TSX VENTURE: IMV) is a vaccine development company focused on the commercialization of its novel vaccine technology and product candidates. The company continues to strengthen its vaccine pipeline through licensing and strategic partnerships to develop therapeutic cancer and infectious disease vaccines.

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future are forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.